Author: Mark Via
Nuclear Receptors: The Pipeline Outlook examines the development pipeline of candidate drugs targeting nuclear receptors and includes figures and tables summarizing the activity in this therapeutic target family.
Key topics covered include:
Current top nuclear receptor drugs and indications
Preclinical and clinical developments
Potential of novel nuclear receptor targets
Profiles of company development activity
New indications for nuclear receptor-targeted drugs
Nuclear receptors are a super family of intra-cellular receptors present in most animal species. They mediate the transcriptional responses to metabolic ligands. In humans, 48 nuclear receptors have been identified. These are characterized as belonging to one of 11 subgroups. The most active targets are the estrogen receptors, glucocorticoid receptors, and progesterone receptors. Some 13% of drugs approved for sale in the United States are nuclear receptors with 15 of these drugs in the top 200 prescribed medicines. These top drugs represented $27.5 billion of sales revenue in 2009. The top-selling drug in this category is GlaxoSmithKline’s drug Advair/Seretide with sales of $7.8 billion in 2009. The major indications for these drugs include asthma, COPD, diabetes type II, hyperlipidemia, contraception, hormone replacement therapy, prostate cancer, and osteoporosis. Clearly nuclear receptors are an important class of targets for pharmaceutical development.
Nuclear Receptors: A Pipeline Overview looks at the clinical and preclinical development activities currently underway. Chapter 1 is an introduction to the nuclear receptor target space with information on sales for the top products and approved indications. Chapter 2 provides a detailed review of the classification and function of nuclear receptor targets in seven subchapter sections. Chapter 3 looks at the potential for nuclear receptors as drug targets and reviews the development pipeline by nuclear receptor target subfamilies, providing descriptions of company activity associated with each target. Chapter 4 examines the progress of nuclear receptortargeted therapeutics for new and known nuclear receptor-related disease and lifestyle indications. Chapter 5 synthesizes the findings of this analysis and presents the likely directions of the nuclear receptor therapeutics market.